Phthalocyanines (Pcs) are a kind of potential
photosensitizers for fluorescence imaging and
photodynamic therapy (
PDT). However, the clinical application of Pcs is suffered from their poor solubility, high aggregation tendency and low
tumor-specificity. To address these problems, two
biotin moieties were linked to the axial positions of
silicon(IV)
phthalocyanine (
SiPc) through hydrophilic
polyethylene glycol (PEG) linkers to synthesize a new water-soluble and
tumor-targeting
photosensitizer (compound 1). The introduction of PEG linkers on
SiPc markedly reduced the aggregation tendency of the conjugate. In vitro assays also proved that compound 1 could specifically accumulate in
biotin receptor (BR) positive Hela cells through the BR-mediated internalization. Owing to the good characteristics of water-solubility and low aggregation, the bioactivity of compound 1 was examined in the xenograft
tumor model. In vivo imaging and tissue distribution studies showed that compound 1 selectively accumulated in the
tumor tissue, with tolerable signals found in other organs of the
tumor-bearing mice. Furthermore, compound 1 could significantly depress
tumor progression in vivo under irradiation. After 14 days of the treatment, the
tumor volumes were even smaller than the beginning size. All these results reveal that compound 1 is a promising candidate, with low aggregation tendency, high
tumor-specificity and water-solubility, for in vivo
tumor diagnosis and
PDT treatment.